Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV Vaccine, Imiquimod, and Metformin in Gynecologic Cancers
NCT06686043Phase 2Recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Vaccines & Immunotherapeutics, Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of qHPV vaccine, imiquimod and metformin 1% gel in cervical carcinoma, vaginal carcinoma and vulvar carcinoma, sponsored by Baylor College of Medicine. Primary endpoint: Progression Free Survival at 24 months. Started Aug 2024; status: recruiting.
02
Drugs
qHPV vaccineimiquimodmetformin 1% gel
03
Conditions
cervical carcinomavaginal carcinomavulvar carcinoma
Beyond the preview
Go deeper on NCT06686043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06686043.